Prevalence, mutual relationship with other genetic lesions, and clinical impact of SF3B1 mutations in CLL. (A) Prevalence of SF3B1 mutations in CLL at diagnosis, in fludarabine-refractory CLL, and in RS; numbers on top indicate the actual number of mutated samples over the total number analyzed. (B) Mutual relationship of SF3B1 mutations with other genetic lesions in CLL at diagnosis and in fludarabine-refractory CLL. In the heat map, rows correspond to identical genes, and columns represent individual patients color-coded based on the gene status (white: wild type; red: mutations of SF3B1, mutations of NOTCH1, mutations and/or deletion of TP53, deletion of ATM). (C) Kaplan-Meier estimates of treatment-free survival (TFS) and overall survival (OS) from diagnosis in the consecutive series of newly diagnosed and previously untreated CLL (n = 301). SF3B1 wild-type (SF3B1 wt) are represented by the blue line. SF3B1 mutated cases (SF3B1 M) are represented by the red line. (D) Gene expression levels of BCL6, AICDA, BCL2, IRF4, and SF3B1 in normal B-cell subpopulations (Naive; centroblasts, CB; centrocytes, CC; memory) and CLL samples. Relative levels of gene expression are depicted with a color scale: red represents the greatest level of expression and blue represents the lowest level.